The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Guggenheim on February 10, 2025. The analyst firm set a price target for $163.00 expecting NBIX to rise to within 12 months (a possible 37.20% upside). 69 analyst firms have reported ratings in the last year.

The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Guggenheim, and Neurocrine Biosciences maintained their buy rating.

The last upgrade for Neurocrine Biosciences Inc happened on August 29, 2024 when Piper Sandler raised their price target to $159. Piper Sandler previously had a neutral for Neurocrine Biosciences Inc.

There is no last downgrade for Neurocrine Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on February 10, 2025 so you should expect the next rating to be made available sometime around February 10, 2026.

While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a maintained with a price target of $165.00 to $163.00. The current price Neurocrine Biosciences (NBIX) is trading at is $118.81, which is out of the analyst’s predicted range.